Gufic Biosciences Limited (NSE:GUFICBIO)

Market Cap	43.81B +18.9%
Revenue (ttm)	9.81B +16.7%
Net Income	734.57M +18.7%
EPS	7.32 +18.7%
Shares Out	n/a
PE Ratio	59.64
Forward PE	n/a
Dividend	0.10 (0.02%)
Ex-Dividend Date	Aug 28, 2026

Volume	15,341
Open	437.45
Previous Close	437.45
Day's Range	430.60 - 441.95
52-Week Range	268.00 - 467.80
Beta	-0.04
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Gufic Biosciences

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (P...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1970
• Employees: 1,607
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: GUFICBIO

Financial Performance

In fiscal year 2026, Gufic Biosciences's revenue was 9.44 billion, an increase of 15.15% compared to the previous year's 8.20 billion. Earnings were 642.15 million, a decrease of -7.80%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 24, 2026

Data Sources Report a data error